A study investigating the efficacy and safety of the combination of iparomlimab and tuvonralimab with or without chemotherapy in second-line and subsequent treatments for recurrent or metastatic head and neck squamous cell carcinoma

Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 1b5888c85ecb2d5d5abb17aa2ed5fd1d42c94e0a
First added on: May 02, 2026